ED
LH icon

Exane Derivatives’s Labcorp LH Stock Holding History

Exane Derivatives’s Portfolio LH Stock Details LH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,381
Closed -$373K – 619
2016
Q4 		$373K Sell
3,381
-33,361
-91% -$3.71M 0.07% 176
2016
Q3 		$4.34M Buy
36,742
+25,102
+216% +$2.96M 0.65% 46
2016
Q2 		$1.3M Buy
+11,640
New +$1.25M 0.22% 72

Other funds holding LH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Exane Derivatives's LH Position: Q1 2017 in Review

Exane Derivatives sold out of Labcorp (LH) in Q1 2017, closing a stake of 3,381 shares — an estimated $373K sold.

Exane Derivatives first reported a position in LH in Q2 2016 and held it in 3 quarters. The position peaked at $4.34M in Q3 2016. 693 funds tracked by Wall St. Rank hold LH as of Q1 2017.

  • Exane Derivatives reported no remaining Labcorp position as of Q1 2017 after selling out during the quarter.
  • Exane Derivatives sold 3,381 Labcorp shares in Q1 2017, an estimated $373K.
  • Exane Derivatives first reported a position in Labcorp in Q2 2016 and held it in 3 quarters.
  • Exane Derivatives's Labcorp position peaked at $4.34M in Q3 2016.
  • 693 funds tracked by Wall St. Rank held Labcorp as of Q1 2017.

Based on Exane Derivatives's 13F filing for Q1 2017, filed 28 Apr 2017.